Athira Pharma Inc expected to post a loss of 44 cents a share - Earnings Preview

LeonaBio

24/02/2025 11:27

* Athira Pharma Inc  ATHA.OQ   ATHA.O  is expected to show
no
change in quarterly revenue when it reports  results on February
26 (estimated) for the period ending December 31 2024
    * 
    * ​LSEG's mean analyst estimate for Athira Pharma Inc is for
a
loss of 44 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Athira
Pharma Inc
is $0.55​, above​ its last closing price of $0.43. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  -0.68       -0.71      -0.75     Missed  -6.2
 Jun. 30 2024  -0.74       -0.74      -0.70     Beat    5
 Mar. 31 2024  -0.79       -0.79      -0.69     Beat    12.7​
 Dec. 31 2023  -0.98       -0.96      -0.71     Beat    26
 ​​Sep.        -0.82       -0.81      -0.87     Missed  -6.9
 30 2023                                                
 Jun. 30 2023  -0.79       -0.78      -0.78     Met     0.4​
 Mar. 31 2023  -0.62       -0.62      -0.73     Missed  -17
 Dec. 31 2022              -0.67      -0.53     Beat    20.9
 This summary was machine generated February 24 at 11:27 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)